Sickle Cell Anemia and Its Phenotypes

Thomas N Williams, Swee Lay Thein, Thomas N Williams, Swee Lay Thein

Abstract

In the 100 years since sickle cell anemia (SCA) was first described in the medical literature, studies of its molecular and pathophysiological basis have been at the vanguard of scientific discovery. By contrast, the translation of such knowledge into treatments that improve the lives of those affected has been much too slow. Recent years, however, have seen major advances on several fronts. A more detailed understanding of the switch from fetal to adult hemoglobin and the identification of regulators such as BCL11A provide hope that these findings will be translated into genomic-based approaches to the therapeutic reactivation of hemoglobin F production in patients with SCA. Meanwhile, an unprecedented number of new drugs aimed at both the treatment and prevention of end-organ damage are now in the pipeline, outcomes from potentially curative treatments such as allogeneic hematopoietic stem cell transplantation are improving, and great strides are being made in gene therapy, where methods employing both antisickling β-globin lentiviral vectors and gene editing are now entering clinical trials. Encouragingly, after a century of neglect, the profile of the vast majority of those with SCA in Africa and India is also finally improving.

Keywords: Africa; genetic modifiers; genetics; genomics; sickle cell anemia.

Figures

Figure 1
Figure 1
Time line of key discoveries and significant events in SCA. Abbreviations: DOVE, Determining Effects of Platelet Inhibition on Vaso-Occlusive Events; FDA, US Food and Drug Administration; Gluβ6Val, substitution of valine for glutamic acid at position 6 of the β-globin chain of hemoglobin; GWAS, genome-wide association study; HbA/F/S, hemoglobin A/F/S; HSCT, hematopoietic stem cell transplantation; MAGiC, Magnesium for Children in Crisis; MSH, Multicenter Study of Hydroxyurea in Sickle Cell Anemia; SCA, sickle cell anemia; SCD, sickle cell disease; STOP, Stroke Prevention Trial in Sickle Cell Anemia; SUSTAIN, Study to Assess Safety and Impact of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Pain Crises; TWiTCH, Transcranial Doppler with Transfusions Changing to Hydroxyurea.
Figure 2. The global distribution of sickle…
Figure 2. The global distribution of sickle cell anemia in relation to the historical distribution of Plasmodium falciparum malaria.
(a) The geospatial distribution of the HbS allele; these data were derived by using a Bayesian geostatistical model with data from published and unpublished population surveys for allele frequencies. (b) The historical distribution of malaria based on Reference . Abbreviation: HbS, hemoglobin S. Figure adapted from Reference .
Figure 3
Figure 3
Pathophysiology, inflammatory stimuli, and cellular interactions in SCA. Polymerization of deoxy-HbS eventually leads to the formation of dehydrated and misshapen erythrocytes, typically with a sickled shape. The sickled cells trigger microvascular occlusion through interactions with activated neutrophils and platelets and adhesion to vascular endothelium, leading to ischemia and tissue hypoxia followed by vasodilation and reperfusion injury. The damaged erythrocytes are short lived, continuously releasing hemoglobin, and oxidized hemoglobin releases heme. Heme functions as a damage-associated molecular pattern that activates endothelial cells, macrophages, and neutrophils and promotes the formation of NETs (NETosis) via TLR4 binding. Abbreviations: HbS, hemoglobin S; NET, neutrophil extracellular trap; NO, nitric oxide; RBC, red blood cell; ROS, reactive oxygen species; SCA, sickle cell anemia; sRBC, sickle red blood cell; VWF, von Willebrand factor.
Figure 4
Figure 4
Common complications of SCA that add to morbidities. While many complications are related to age, it is also clear that some patients are genetically predisposed to some complications. Predisposing or protective genetic variants have been identified for some complications, such as bilirubin levels and gallstones, as well as sickle nephropathy. Clearly some patients are also predisposed to stroke, avascular necrosis, and pulmonary complications, but genetic variants for these complications need genetic and functional validation. Abbreviation: SCA, sickle cell anemia.

References

    1. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351:959.
    1. Adams R, McKie V, Nichols F, Carl E, Zhang D-L, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605–10.
    1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.
    1. Adewoye AH, Nolan VG, Ma Q, Baldwin C, Wyszynski DF, et al. Association of polymorphisms of IGF1R and genes in the transforming growth factor–β/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis. 2006;43:593–98.
    1. Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, et al. Priapism in sickle-cell disease; incidence, risk factors and complications – an international multicentre study. BJU Int. 2002;90:898–902.
    1. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97:3313–14.
    1. Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? BrJ Haematol. 2004;126:606–11.
    1. Amin BR, Bauersachs RM, Meiselman HJ, Mohandas N, Hebbel RP, et al. Monozygotic twins with sickle cell anemia and discordant clinical courses: clinical and laboratory studies. Hemoglobin. 1991;15:247–56.
    1. Andrade FL, Annichino-Bizzacchi JM, Saad ST, Costa FF, Arruda VR. Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol. 1998;59:46–50.
    1. Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood. 2008;111:5721–26.
    1. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol. 2011;155:386–94.
    1. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2016;376:429–39.
    1. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043) Br J Haematol. 2011;153:92–104.
    1. Ataga KI, Smith WR, DeCastro LM, Swerdlow P, Saunthararajah Y, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111:3991–97.
    1. Baldwin C, Nolan VG, Wyszynski DF, Ma QL, Sebastiani P, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood. 2005;106:372–75.
    1. Ballas SK. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood. 2013;121:243–44.
    1. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120:3647–56.
    1. Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342:253–57.
    1. Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA, et al. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood. 2012;120:3822–28.
    1. Beet EA. The genetics of the sickle-cell trait in a Bantu tribe. Ann Eugen. 1949;14:279–84.
    1. Belisario AR, Nogueira FL, Rodrigues RS, Toledo NE, Cattabriga AL, et al. Association of alpha-thalassemia, TNF-alpha (-308G>A) and VCAM-1(c.1238G>C) gene polymorphisms with cerebrovascular disease in a newborn cohort of 411 children with sickle cell anemia. Blood Cells Mol Dis. 2015;54:44–50.
    1. Belisario AR, Sales RR, Toledo NE, Velloso-Rodrigues C, Silva CM, Viana MB. Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia. Blood. 2015;126:1259–60.
    1. Bensinger TA, Gillette PN. Hemolysis in sickle cell disease. Arch Intern Med. 1974;133:624–31.
    1. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117:1130–40.
    1. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Vasile M, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125:1653–61.
    1. Bernaudin F, Verlhac S, Chevret S, Torres M, Coic L, et al. G6PD deficiency, absence of α-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112:4314–17.
    1. Berry PA, Cross TJ, Thein SL, Portmann BC, Wendon JA, et al. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. Clin Gastroenterol Hepatol. 2007;5:1469–76.
    1. Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, et al. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. J Hum Genet. 2011;56:316–23.
    1. Bianchi E, Zini R, Salati S, Tenedini E, Norfo R, et al. c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood. 2010;116:e99–110.
    1. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, et al. HLA-haploidentical bone marrow transplantation with post-transplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–91.
    1. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14:e2–12.
    1. Breda L, Motta I, Lourenco S, Gemmo C, Deng W, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 2016;128:1139–43.
    1. Brendel C, Guda S, Renella R, Bauer DE, Canver MC, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Investig. 2016;126:3868–78.
    1. Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017;178:319–26.
    1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–69.
    1. Camus SM, De Moraes JA, Bonnin P, Abbyad P, Le Jeune S, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125:3805–14.
    1. Canver MC, Orkin SH. Customizing the genome as therapy for the β-hemoglobinopathies. Blood. 2016;127:2536–45.
    1. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84:643–49.
    1. Castro V, Alberto FL, Costa RN, Lepikson-Neto J, Gualandro SF, et al. Polymorphism of the human platelet antigen-5 system is a risk factor for occlusive vascular complications in patients with sickle cell anemia. Vox Sang. 2004;87:118–23.
    1. Cavazzana M, Antoniani C, Miccio A. Gene therapy for β-hemoglobinopathies. Mol Ther. 2017;25:1142–54.
    1. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467:318–22.
    1. Chaar V, Kéclard L, Diara JP, Leturdu C, Elion J, et al. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia. Haematologica. 2005;90:188–99.
    1. Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine. 2013;31:3872–78.
    1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317–22.
    1. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123:3818–27.
    1. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematol Am Soc Hematol Educ Program. 2013;2013:439–46.
    1. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062–71.
    1. Costa RN, Conran N, Albuquerque DM, Soares PH, Saad ST, Costa FF. Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia. Haematologica. 2005;90:977–79.
    1. Cox SE, Makani J, Soka D, L’Esperence VS, Kija E, et al. Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania. Br J Haematol. 2014;165:699–706.
    1. Day TG, Drasar ER, Fulford T, Sharpe CC, Thein SL. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica. 2012;97:201–5.
    1. De Castro LM, Zennadi R, Jonassaint JC, Batchvarova M, Telen MJ. Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci. 2012;5:437–44.
    1. de Montalembert M, Dumont MD, Heilbronner C, Brousse V, Charrara O, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96:801–7.
    1. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699–710.
    1. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127:829–38.
    1. DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012;119:3684–90.
    1. Deng W, Rupon JW, Krivega I, Breda L, Motta I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158:849–60.
    1. Dominical VM, Samsel L, Nichols JS, Costa FF, McCoy JP, Jr, et al. Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica. 2014;99:e214–17.
    1. Dominical VM, Vital DM, O’Dowd F, Saad ST, Costa FF, Conran N. In vitro microfluidic model for the study of vaso-occlusive processes. Exp Hematol. 2015;43:223–28.
    1. Drasar ER, Igbineweka N, Vasavda N, Free M, Awogbade M, et al. Blood transfusion usage among adults with sickle cell disease – a single institution experience over ten years. Br J Haematol. 2011;152:766–70.
    1. Drasar ER, Menzel S, Fulford T, Thein SL. The effect of Duffy antigen receptor for chemokines on severity in sickle cell disease. Haematologica. 2013;98:e87.
    1. Driscoll MC, Hurlet A, Styles L, McKie V, Files B, et al. Stroke risk in siblings with sickle cell anemia. Blood. 2003;101:2401–4.
    1. Du E, Diez-Silva M, Kato GJ, Dao M, Suresh S. Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis. PNAS. 2015;112:1422–27.
    1. Dufu K, Lehrer-Graiwer J, Ramos E, Oksenberg D. GBT440 inhibits sickling of sickle cell trait blood under in vitro conditions mimicking strenuous exercise. Hematol Rep. 2016;8:6637.
    1. Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;129:2719–26.
    1. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun. 1968;33:129–35.
    1. Elliott L, Ashley-Koch AE, De Castro L, Jonassaint J, Price J, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol. 2007;137:262–67.
    1. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391–401.
    1. Embury SH, Dozy AM, Miller J, Davis JR, Kleman KM, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med. 1982;306:270–74.
    1. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, et al. (Prophyl. Penicillin Study II). 1995. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr. 127:685–90.
    1. Fertrin KY, Melo MB, Assis AM, Saad ST, Costa FF. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clin Genet. 2003;64:160–62.
    1. Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, et al. Genetic predictors for stroke in children with sickle cell anemia. Blood. 2011;117:6681–84.
    1. Flanagan JM, Sheehan V, Linder H, Howard TA, Wang YD, et al. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood. 2013;121:3237–45.
    1. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Bailliére’ Clin Haematol. 1998;11:1–51.
    1. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39:112–18.
    1. Frelinger AL, III, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, et al. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014;25:27–35.
    1. Galarneau G, Coady S, Garrett ME, Jeffries N, Puggal M, et al. Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients. Blood. 2013;122:434–42.
    1. Gardner K, Thein SL. Super-elevated LDH and thrombocytopenia are markers of a severe subtype of vaso-occlusive crisis in sickle cell disease. Am J Hematol. 2015;90:E206–7.
    1. Geard A, Pule GD, Chetcha Chemegni B, Ngo Bitoungui VJ, Kengne AP, et al. Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol. 2017;178:629–39.
    1. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–45.
    1. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86:776–83.
    1. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–95.
    1. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–56.
    1. Goldstein J, Konigsberg W, Hill RJ. The structure of human hemoglobin: VI. The sequence of amino acids in the tryptic peptides of the β chain. J Biol Chem. 1963;238:2016–27.
    1. Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016;7:302–15.
    1. Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127:820–28.
    1. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/β+ thalassemia. Blood. 2001;97:3998–99.
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41:S398–405.
    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–21.
    1. Hatton CS, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. Br Med J. 1985;290:744–45.
    1. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am J Heematol. 2011;86:123–54.
    1. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374:625–35.
    1. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med. 2003;141:279–82.
    1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517–21.
    1. Hicks EJ, Griep JA, Nordschow CD. Comparison of results for three methods of hemoglobin S identification. Clin Chem. 1973;19:533–35.
    1. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15:384–91.
    1. Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 2016;127:839–48.
    1. Hoppe C, Klitz W, Cheng S, Apple R, Steiner L, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood. 2004;103:2391–96.
    1. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood. 2003;101:2865–69.
    1. Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312:48–56.
    1. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326–28.
    1. Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, et al. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol. 2000;111:474–81.
    1. Jiang J, Best S, Menzel S, Silver N, Lai MI, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108:1077–83.
    1. Joishy SK, Griner PF, Rowley PT. Sickle β-thalassemia: identical twins differing in severity implicate nongenetic factors influencing course. Am J Hematol. 1976;1:23–33.
    1. Kan YW, Dozy AM. Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells. Lancet. 1978;312:910–12.
    1. Kanter J, Telen MJ, Hoppe C, Roberts CL, Kim JS, Yang X. Validation of a novel point of care testing device for sickle cell disease. BMC Med. 2015;13:225.
    1. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
    1. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640–45.
    1. Kutlar A, Kutlar F, Turker I, Tural C. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin. 2001;25:213–17.
    1. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol. 1999;66:411–15.
    1. Lebensburger JD, Palabindela P, Howard TH, Feig DI, Aban I, Askenazi DJ. Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome. Pediatr Nephrol. 2016;31:1363–68.
    1. Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108:847–52.
    1. Leonardo FC, Brugnerotto AF, Domingos IF, Fertrin KY, de Albuquerque DM, et al. Reduced rate of sickle-related complications in Brazilian patients carrying HbF-promoting alleles at the BCL11A and HMIP-2 loci. Br J Haematol. 2016;173:456–60.
    1. Lettre G, Sankaran VG, Bezerra MA, Araújo AS, Uda M, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. PNAS. 2008;105:11869–74.
    1. Lionnet F, Hammoudi N, Stojanovic KS, Avellino V, Grateau G, et al. Hemoglobin SC disease complications: a clinical study of 179 cases. Haematologica. 2012;97:1136–41.
    1. Lysenko AJ, Semashko IN. In: Itogi Nauki: Medicinskaja Geografija. Lebedew AW, editor. Acad. Sci. USSR; Moscow (in Russian): 1968. Geography of malaria. A medico-geographic profile of an ancient disease; pp. 25–146.
    1. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68:92–102.
    1. Makani J, Menzel S, Nkya S, Cox SE, Drasar ER, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood. 2011;117:1390–92.
    1. Malar. Genom. Epidemiol. Netw. Reappraisal of known malaria resistance loci in a large multicenter study. Nat Genet. 2014;46:1197–204.
    1. Martin OO, Moquist KL, Hennessy JM, Nelson SC. Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era. Pediatr Blood Cancer. 2018;65:e26713
    1. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012;58:945–49.
    1. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307:1254–56.
    1. Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39:1197–99.
    1. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017;8:321–26.
    1. Milton JN, Sebastiani P, Solovieff N, Hartley SW, Bhatnagar P, et al. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLOS ONE. 2012;7:e34741.
    1. Misra H, Bainbridge J, Berryman J, Abuchowski A, Galvez KM, et al. A Phase Ib open label, randomized, safety study of SANGUINATE in patients with sickle cell anemia. Rev Bras Hematol Hemoter. 2017;39:20–27.
    1. Moat SJ, Rees D, George RS, King L, Dodd A, et al. Newborn screening for sickle cell disorders using tandem mass spectrometry: three years’ experience of using a protocol to detect only the disease states. Ann Clin Biochem. 2017;54:601–11.
    1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–87.
    1. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;111:402–10.
    1. Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science. 1987;237:500–6.
    1. Mtatiro SN, Singh T, Rooks H, Mgaya J, Mariki H, et al. Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. PLOS ONE. 2014;9:e111464.
    1. Mushemi-Blake S, Melikian N, Drasar ER, Bhan A, Lunt A, et al. Pulmonary haemodynamics in sickle cell disease are driven predominantly by a high-output state rather than elevated pulmonary vascular resistance: a prospective 3-dimensional echocardiography/Doppler study. PLOS ONE. 2015;10:e0135472.
    1. Natl. Heart Lung Blood Inst. Evidence-based management of sickle cell disease: expert panel report, 2014. Evid Rep. US Dep. Health Hum. Serv; Washington, DC: 2014.
    1. Natl Inst Health. Sickle cell disease in sub-Saharan Africa: collaborative consortium (U24). Funding Oppor Announc. RFA-HL-17-006. Natl Inst Health; Bethesda, MD: 2016. .
    1. Navalkele P, Ozgonenel B, McGrath E, Lephart P, Sarnaik S. Invasive pneumococcal disease in patients with sickle cell disease. J Pediatr Hematol Oncol. 2017;39:341–44.
    1. Nebor D, Broquere C, Brudey K, Mougenel D, Tarer V, et al. Alpha-thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients. Blood Cells Mol Dis. 2010;45:154–58.
    1. Nebor D, Durpes MC, Mougenel D, Mukisi-Mukaza M, Elion J, et al. Association between Dufiy antigen receptor for chemokines expression and levels of inflammation markers in sickle cell anemia patients. Clin Immunol. 2010;136:116–22.
    1. Neel JV. The inheritance of sickle cell anemia. Science. 1949;110:64–66.
    1. Nolan VG, Adewoye A, Baldwin C, Wang L, Ma Q, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-β/BMP pathway. Br J Haematol. 2006;133:570–78.
    1. Nolan VG, Baldwin C, Ma Q, Wyszynski DF, Amirault Y, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2005;128:266–72.
    1. Oder E, Safo MK, Abdulmalik O, Kato GJ. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol. 2016;175:24–30.
    1. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94.
    1. Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175:141–53.
    1. Olujohungbe AB, Adeyoju A, Yardumian A, Akinyanju O, Morris J, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial—the Priapism in Sickle Cell Study. J Androl. 2011;32:375–82.
    1. Optim Prim Stroke Prev Sickle Cell Anemia (STOP 2) Trial Investig. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.
    1. Orringer EP, Casella JF, Ataga K, Koshy M, Adams-Graves P, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286:2099–106.
    1. Pagnier J, Mears JG, Dunda-Belkhodja O, Schaefer-Rego KE, Beldjord C, et al. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. PNAS. 1984;81:1771–73.
    1. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365:44–53.
    1. Passon RG, Howard TA, Zimmerman SA, Schultz WH, Ware RE. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1a promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. Am J Pediatr Hematol Oncol. 2001;23:448–51.
    1. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 1949;110:543–48.
    1. Penkert RR, Young NS, Surman SL, Sealy RE, Rosch J, et al. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease. Vaccine. 2017;35:3615–20.
    1. Perkins A, Xu X, Higgs DR, Patrinos GP, Arnaud L, et al. Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood. 2016;127:1856–62.
    1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.
    1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–51.
    1. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weatherall DJ. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health. 2014;2:e80–89.
    1. Piel FB, Tewari S, Brousse V, Analitis A, Font A, et al. Associations between environmental factors and hospital admissions for sickle cell disease. Haematologica. 2017;102:666–75.
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.
    1. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Investig. 1984;74:652–56.
    1. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. PNAS. 1993;90:5039–43.
    1. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010;30:2392–99.
    1. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 2005;84:363–76.
    1. Proenca-Ferreira R, Brugnerotto AF, Garrido VT, Dominical VM, Vital DM, et al. Endothelial activation by platelets from sickle cell anemia patients. PLOS ONE. 2014;9:e89012.
    1. Quek L, Sharpe C, Dutt N, Height S, Allman M, et al. Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease. Br J Haematol. 2010;149:289–91.
    1. Reading NS, Shooter C, Song J, Miller R, Agarwal A, et al. Loss of major DNase I hypersensitive sites in duplicated β-globin gene cluster incompletely silences HBB gene expression. Hum Mutat. 2016;37:1153–56.
    1. Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, et al. A double-blind,placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014;89:709–13.
    1. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003;10:99–107.
    1. Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–55.
    1. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, et al. Enzymatic amplification of betaglobin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–54.
    1. Sandor B, Marin M, Lapoumeroulie C, Rabaï M, Lefevre SD, et al. Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia. Br J Haematol. 2016;173:145–49.
    1. Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460:1093–97.
    1. Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, et al. APOL1 α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica. 2017;102:e1–6.
    1. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood. 2008;112:3927–38.
    1. Scott JA, Berkley JA, Mwangi I, Ochola L, Uyoga S, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet. 2011;378:1316–23.
    1. Serjeant GR, Serjeant BE, Mason KP, Hambleton IR, Fisher C, Higgs DR. The changing face of homozygous sickle cell disease: 102 patients over 60 years. IntJ Lab Hematol. 2009;31:585–96.
    1. Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981;318:595–97.
    1. Sharan K, Surrey S, Ballas S, Borowski M, Devoto M, et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol. 2004;124:240–43.
    1. Shooter C, Senior McKenzie T, Oakley M, Jacques T, Clark B, Thein SL. First reported duplication of the entire beta globin gene cluster causing an unusual sickle cell trait phenotype. Br J Haematol. 2015;170:128–31.
    1. Shriner D, Rotimi CN. Whole-genome-sequence-based haplotypes reveal single origin of the sickle allele during the Holocene Wet Phase. Am J Hum Genet. 2018;102:547–56.
    1. Stadhouders R, Aktuna S, Thongjuea S, Aghajanirefah A, Pourfarzad F, et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J Clin Investig. 2014;124:1699–710.
    1. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;33:259–71.
    1. Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol. 2006;13:131–36.
    1. Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood. 1986;68:985–90.
    1. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, editors. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. 2nd ed. Cambridge Univ Press; Cambridge, UK: 2009.
    1. Styles L, Hoppe C, Klitz W, Vichinsky E, Lubin B, Trachtenberg E. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood. 2000;95:3562–67.
    1. Sullivan KJ, Kissoon N, Duckworth LJ, Sandler E, Freeman B, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med. 2001;164:2186–90.
    1. Tallack MR, Perkins AC. Three fingers on the switch: Krüppel-like factor 1 regulation of γ-globin to β-globin gene switching. Curr Opin Hematol. 2013;20:193–200.
    1. Tamouza R, Busson M, Fortier C, Diagne I, Diallo D, et al. HLA-E*0101 allele in homozygous state favors severe bacterial infections in sickle cell anemia. Hum Immunol. 2007;68:849–53.
    1. Tang DC, Prauner R, Liu W, Kim KH, Hirsch RP, et al. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol. 2001;68:164–69.
    1. Tantawy AA, Adly AA, Ismail EA, Aly SH. Endothelial nitricoxide synthase gene intron 4 VNTR polymorphism in sickle cell disease: relation to vasculopathy and disease severity. Pediatr Blood Cancer. 2015;62:389–94.
    1. Taylor JG, VI, Tang DC, Savage SA, Leitman SF, Heller SI, et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood. 2002;100:4303–9.
    1. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127:810–19.
    1. Telen MJ, Wun T, McCavit TL, De Castro LM, Krishnamurti L, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125:2656–64.
    1. Thein SL, Menzel S, Peng X, Best S, Jiang J, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. PNAS. 2007;104:11346–51.
    1. Traeger-Synodinos J, Harteveld CL. Advances in technologies for screening and diagnosis of hemoglobinopathies. Biomark Med. 2014;8:119–31.
    1. Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22:987–90.
    1. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. PNAS. 2002;99:3047–51.
    1. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. PNAS. 2008;105:1620–25.
    1. Ulug P, Vasavda N, Awogbade M, Cunningham J, Menzel S, Thein SL. Association of sickle avascular necrosis with bone morphogenic protein 6. Ann Hematol. 2009;88:803–5.
    1. UN Gen. Assem. Resolution adopted by the General Assembly: 55/2 United Nations Millennium Declaration. UN Gen. Assembly; New York: 2000. Resolut. 55/2.
    1. van Hamel Parsons V, Gardner K, Patel R, Thein S. Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK. Ann Hematol. 2016;95:227–32.
    1. Vasavda N, Badiger S, Rees D, Height S, Howard J, Thein SL. The presence of α-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. Br J Haematol. 2008;143:589–92.
    1. Vasavda N, Menzel S, Kondaveeti S, Maytham E, Awogbade M, et al. The linear effects of α-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol. 2007;138:263–70.
    1. Vicari P, Adegoke SA, Mazzotti DR, Cancado RD, Nogutti MA, Figueiredo MS. Interleukin-1 β and interleukin-6 gene polymorphisms are associated with manifestations of sickle cell anemia. Blood Cells Mol Dis. 2015;54:244–49.
    1. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, et al. Natl Acute Chest Syndr Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342:1855–65.
    1. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89:1787–92.
    1. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169:746–53.
    1. Vierstra J, Reik A, Chang KH, Stehling-Sun S, Zhou Y, et al. Functional footprinting of regulatory DNA. Nat Methods. 2015;12:927–30.
    1. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110:2166–72.
    1. Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98:1802–11.
    1. Wali Y, Beshlawi I, Fawaz N, Alkhayat A, Zalabany M, et al. Coexistence of sickle cell disease and severe congenital neutropenia: first impressions can be deceiving. Eur J Haematol. 2012;89:245–49.
    1. Wang WC, Pavlakis SG, Helton KJ, McKinstry RC, Casella JF, et al. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer. 2008;51:643–46.
    1. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300–11.
    1. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661–70.
    1. Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) Blood. 2012;119:3925–32.
    1. Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010;156:66–70.
    1. Weatherall MW, Higgs DR, Weiss H, Weatherall DJ, Serjeant GR. Phenotype/genotype relationships in sickle cell disease: a pilot twin study. Clin Lab Haematol. 2005;27:384–90.
    1. Wienert B, Funnell AP, Norton LJ, Pearson RC, Wilkinson-White LE, et al. Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin. Nat Commun. 2015;6:7085.
    1. Williams TN. In: Advances in Malaria Research. Gaur D, Chitnis CE, Chauhan VS, editors. Wiley & Sons; Hoboken, NJ: 2016. Host genetics; pp. 465–94.
    1. Wilmore DW. Food and Drug Administration approval of glutamine for sickle cell disease: success and precautions in glutamine research. J Parenter Enter Nutr. 2017;41:912–17.
    1. Wilson JT, Milner PF, Summer ME, Nallaseth FS, Fadel HE, et al. Use of restriction endonucleases for mapping the allele for βS-globin. PNAS. 1982;79:3628–31.
    1. Wonkam A, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Cooper RS, et al. Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon. PLOS ONE. 2014;9:e92506.
    1. World Health Organ. Sickle-cell anaemia: report by the Secretariat. World Health Organ; Geneva: 2006. Provisional Agenda Item 11.4. .
    1. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and plateleterythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507–16.
    1. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011;334:993–96.
    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.
    1. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120:528–37.
    1. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:801–9.
    1. Zhang X, Zhang W, Ma SF, Desai AA, Saraf S, et al. Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation. 2014;129:1650–58.
    1. Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol. 1998;59:267–72.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다